In a filing, Centessa Pharmaceuticals plc ADR revealed its Chief Executive Officer SAHA SAURABH unloaded Company’s shares for reported $0.57 million on Aug 23 ’24. In the deal valued at $12.30 per share,46,651 shares were sold. As a result of this transaction, SAHA SAURABH now holds 776,924 shares worth roughly $9.98 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Weinhoff Gregory M sold 17,802 shares, generating $218,792 in total proceeds. Upon selling the shares at $12.29, the Chief Business Officer now owns 223,369 shares.
Before that, Weinhoff Gregory M sold 12,198 shares. Centessa Pharmaceuticals plc ADR shares valued at $148,430 were divested by the Chief Business Officer at a price of $12.17 per share. As a result of the transaction, Weinhoff Gregory M now holds 241,171 shares, worth roughly $3.1 million.
Oppenheimer initiated its Centessa Pharmaceuticals plc ADR [CNTA] rating to an Outperform in a research note published on July 18, 2024; the price target was $14. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in mid November from “a Hold” to “a Buy”. Morgan Stanley also remained covering CNTA and has increased its forecast on October 26, 2023 with a “an Equal-weight” recommendation from previously “an Underweight” rating. Evercore ISI started covering the stock on June 21, 2023. It rated CNTA as “an Outperform”.
Price Performance Review of CNTA
On Friday, Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] saw its stock jump 5.33% to $12.85. Over the last five days, the stock has gained 2.80%. Centessa Pharmaceuticals plc ADR shares have risen nearly 61.43% since the year began. Nevertheless, the stocks have risen 91.79% over the past one year. While a 52-week high of $13.56 was reached on 08/15/24, a 52-week low of $5.15 was recorded on 01/11/24. SMA at 50 days reached $10.21, while 200 days put it at $9.20.
Levels Of Support And Resistance For CNTA Stock
The 24-hour chart illustrates a support level at 12.25, which if violated will result in even more drops to 11.66. On the upside, there is a resistance level at 13.19. A further resistance level may holdings at 13.54. The Relative Strength Index (RSI) on the 14-day chart is 66.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 20.75%. Stochastics%K at 72.86% indicates the stock is a holding.
How much short interest is there in Centessa Pharmaceuticals plc ADR?
A steep rise in short interest was recorded in Centessa Pharmaceuticals plc ADR stocks on 2024-07-31, growing by 0.24 million shares to a total of 1.38 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 1.14 million shares. There was a rise of 17.46%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 12, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $9 price target.
